Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
6.56
-0.25 (-3.67%)
At close: Mar 20, 2026, 4:00 PM EDT
6.57
+0.01 (0.15%)
After-hours: Mar 20, 2026, 4:10 PM EDT

Kalaris Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
151193----
Enterprise Value
75.18108.520000
Last Close Price
6.568.44----
PE Ratio
--2.96----
PB Ratio
2.942.45----
P/TBV Ratio
1.271.64----
P/FCF Ratio
--5.01----
P/OCF Ratio
--5.04----
EV/EBITDA Ratio
--2.35----
EV/EBIT Ratio
--2.35----
EV/FCF Ratio
--2.81----
Debt / Equity Ratio
0.420.42-1.020.110.130.10
Debt / EBITDA Ratio
-0.73-0.73-1.00-0.14-0.21-0.18
Debt / FCF Ratio
-0.87-0.87-2.50-0.22-0.25-0.28
Net Debt / Equity Ratio
-1.07-1.07-0.52-1.07-0.88-0.97
Net Debt / EBITDA Ratio
1.831.83-0.970.791.161.29
Net Debt / FCF Ratio
2.192.19-2.421.261.402.05
Quick Ratio
12.1512.150.076.499.616.56
Current Ratio
12.2312.230.116.619.996.69
Return on Equity (ROE)
-308.10%-308.10%-145.36%-102.85%-75.02%-59.47%
Return on Assets (ROA)
-72.17%-72.17%-52.53%-85.39%-60.65%-51.97%
Return on Invested Capital (ROIC)
-1698.01%-1698.01%1471.54%-2451.00%-942.93%-2139.91%
Return on Capital Employed (ROCE)
-98.74%-98.74%-71.91%-96.30%-68.28%-55.93%
Earnings Yield
-36.82%-33.77%----
FCF Yield
-26.12%-19.95%----
Buyback Yield / Dilution
-25.87%-25.87%----
Updated Mar 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q